Endo Pharmaceuticals
PharmaMalvern, Pennsylvania, United States · Est. 1991 · 1,000 employees
Endo Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing branded and generic pharmaceuticals for pain management, aesthetics, and other specialized therapeutic areas.
0
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
0
Indications↗
Distinct diseases across all programs
98
Clinical Trials↗
All sponsored trials (all statuses)
3
Orange Book Patents
Across 1 drug with upcoming expirations
Activity
Key Events
Jul 14, 2026TrialA Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (PFI) (Also Known as Ledderhose Disease)
Jul 10, 2025FDAGocovri — GOCOVRI
Jan 3, 2024TrialA Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)
Jun 15, 2022TrialStudy of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks
Feb 14, 2022TrialLong-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis
Nov 29, 2021TrialEfficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
Feb 1, 2021FDAGocovri — GOCOVRI
Dec 28, 2020TrialEffects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite
4 more events
Dec 17, 2020TrialLong-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)
Oct 1, 2020TrialCCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques
Jul 29, 2020TrialSafety and Efficacy of EN3835 in Participants With Frozen Shoulder
Jun 30, 2020TrialA Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
Details
Company Info
Company Overview
$100.0M
Mkt Cap
$700.0M
Revenue
—
Cash
CEOBlaise Coleman
Founded1991
Employees1,000
HQMalvern, Pennsylvania, United States
Websiteendo.com
LinkedInCompany Page
Therapeutic Focus
Pain managementSpecialty pharmaceuticalsAesthetics
Regulatory
Regulatory Timeline
19827 events
FDAJan 1
Opana — NUMORPHAN
Application NDA011738 (NDA)
FDAJan 1
Opana — OPANA
Application NDA011707 (NDA)
FDAJan 1
Moban — MOBAN
Application NDA017111 (NDA)
FDAJan 1
Moban — MOBAN
Application NDA017938 (NDA)
FDAJan 1
Gocovri — SYMMETREL
Application NDA018101 (NDA)
FDAJan 1
Gocovri — SYMMETREL
Application NDA016020 (NDA)
FDAJan 1
Gocovri — SYMMETREL
Application NDA016023 (NDA)
20062 events
FDAJun 22
Opana — OPANA
Application NDA021611 (NDA)
FDAJun 22
Opana — OPANA ER
Application NDA021610 (NDA)
20111 event
FDADec 9
Opana — OPANA ER
Application NDA201655 (NDA)
20172 events
FDAAug 24
Gocovri — GOCOVRI
Application NDA208944 (NDA)
FDAAug 24
Gocovri — GOCOVRI
Application NDA208944
20181 event
FDAFeb 16
Gocovri — OSMOLEX ER
Application NDA209410 (NDA)
20201 event
FDAMar 10
Gocovri — GOCOVRI
Application NDA208944
20211 event
FDAFeb 1
Gocovri — GOCOVRI
Application NDA208944
20251 event
FDAJul 10
Gocovri — GOCOVRI
Application NDA208944
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)